Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Observational Study to Evaluate the Safety and Efficacy of NovoMix® 70 in Type 2 Diabetes
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 619
- Registration Number
- NCT00704223
Observational Study to Evaluate the Safety and Efficacy of Levemir® in Type 2 Diabetes
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1976
- Registration Number
- NCT00700830
Observational Study to Evaluate the Safety While Using Levemir®
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3593
- Registration Number
- NCT00701155
Observational Study Describing Conditions for Administering Slow-acting Insulin Analogue With Oral Antidiabetic Agents in Type 2 Diabetes on Blood Glucose Control
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2745
- Registration Number
- NCT00700960
- Locations
- 🇫🇷
Novo Nordisk Investigational Site, Paris La Défense, France
An Observational Study to Assess Safety and Effectiveness of Intravenous NovoRapid® in Hospitalised Subjects
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3024
- Registration Number
- NCT00700648
- Locations
- 🇮🇳
Novo Nordisk Investigational Site, Bangalore, India
Observational Study to Evaluate Safety of Levemir® in Type 1 and Type 2 Diabetes
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1531
- Registration Number
- NCT00700765
- Locations
- 🇮🇩
Novo Nordisk Investigational Site, Jakarta, Indonesia
The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 665
- Registration Number
- NCT00700817
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom
Observational Study of Patients Using NovoRapid® or Soluble Human Insulin for Treatment of Type 2 Diabetes
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 4099
- Registration Number
- NCT00698126
- Locations
- 🇮🇹
Novo Nordisk Investigational Site, Rome, Italy
Observational Study to Evaluate the Efficacy and Safety of NovoMix® 30 in Type 1 and 2 Diabetes
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2308
- Registration Number
- NCT00699179
- Locations
Novo Nordisk Investigational Site, Belgrade, Former Serbia and Montenegro
Safety and Efficacy of Biphasic Human Insulin Compared to EX1000 in Type 2 Diabetes
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 397
- Registration Number
- NCT00698802
© Copyright 2024. All Rights Reserved by MedPath